Browsing by Author "Canpolat, Cengiz"
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
Item Aşırı Kilo Kaybının Nadir Bir Nedeni: Diensefalik Sendromlu Üç Olgu(Acıbadem Mehmet Ali Aydınlar Üniversitesi, 2017-01-01) Işık, Uğur; Kuter Yılancıoğlu, Şebnem; Eryılmaz, Sema; Canpolat, CengizÖzet Diensefalik sendrom, daha çok erken çocukluk döneminde görülen, yaygın kilo kaybı ve cilt altı yağ dokusu kaybı, aşırı hareketlilik, öfori ve aşırı uyanıklık durumu ile karakterize bir sendromdur. Genellikle hipotalamik-optik ki azmatik bölgenin yer kaplayıcı neoplastik oluşumlarına eşlik eder. Kitle boyutu ile kilo alımı arasında ters orantı mevcuttur. Bu olgu sunumunda kliniğimizde hipotalamik-optik kiazmatik gliom tanısı ile tedavi alan ve boy uza ması devam ettiği halde aşırı kilo kaybı olan ve tartıları -2 standart sapmanın altında izlenen 1 yaş altı 3 olgu, endokrinolojik incelemeleri ile birlikte literatür bilgileri ışığında değerlendirilerek sunulmuştur. Kilo alımında duraklamanın ender de olsa önemli nedenlerinden birinin diensefalik sendrom olabileceğine dikkat çekilmiştir.Item Diagnostic Role of sCD14-Subtype as a Sepsis Biomarker in Febrile Neutropenic Pediatric Oncology Patients(Acıbadem Mehmet Ali Aydınlar Üniversitesi, 2018-09-01) Kuter, Şebnem; Canpolat, Cengiz; Yılancıoğlu, KaanABSTRACT Introduction and Objective: Febrile neutropenia (FN) is one of the most common complications of cancer chemotherapy and requires urgent treatment. Upon diagnosis of childhood FN, culture samples should be obtained and a broad spectrum antibiotherapy should be administered immediately. However, bacterial infections are not the only cause of fever in neutropenic pediatric patients; chemotherapeutics, the disease itself, as well as viral and fungal agents can also be the cause of fever. Various biomarkers have been studied to differentiate the cause of fever to date. Infections are mostly lethal in neutropenic patients, early stage differential biomarkers are, therefore, of utmost importance. It is the aim of this study to assess the potential of presepsin as an additional diagnostic tool for the detection of bacteremia/sepsis in childhood Febrile Neutropenia (FN) patients. Methods: Twenty-four pediatric patients, with a total 29 febrile neutropenic episodes were enrolled in this study. One patient with 3 FN episodes, three patients with 2 FN episodes were admitted to our clinic during the study. Patients were classified into bacteremia/sepsis and fever without origin groups. Serum samples were collected after confirmation of FN and analyzed for presepsin, c-reactive protein (CRP) and procalcitonin (PCT) according to instructions of manufacturers. Results: Biomarkers failed to display a discriminative value between bacteremia/sepsis and fever without origin groups, whereas presepsin was found to be an indicator of the presence of bacterial growth in hemoculture and was shown to have a potential diagnostic value. Conclusion: Presepsin might be used as an additional diagnostic tool for the detection of bacteremia/sepsis in childhood FN patients.Item Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options(NATURE PUBLISHING GROUP, 2015-01-01) Fischer, Ute; Forster, Michael; Rinaldi, Anna; Risch, Thomas; Sungalee, Stephanie; Warnatz, Hans-Joerg; Bornhauser, Beat; Gombert, Michael; Kratsch, Christina; Stuetz, Adrian M.; Sultan, Marc; Tchinda, Joelle; Worth, Catherine L.; Amstislavskiy, Vyacheslav; Badarinarayan, Nandini; Baruchel, Andre; Bartram, Thies; Basso, Giuseppe; Canpolat, Cengiz; Cario, Gunnar; Cave, Helene; Dakaj, Dardane; Delorenzi, Mauro; Dobay, Maria Pamela; Eckert, Cornelia; Ellinghaus, Eva; Eugster, Sabrina; Frismantas, Viktoras; Ginzel, Sebastian; Haas, Oskar A.; Heidenreich, Olaf; Hemmrich-Stanisak, Georg; Hezaveh, Kebria; Hoell, Jessica I.; Hornhardt, Sabine; Husemann, Peter; Kachroo, Priyadarshini; Kratz, Christian P.; te Kronnie, Geertruy; Marovca, Blerim; Niggli, Felix; McHardy, Alice C.; Moorman, Anthony V.; Panzer-Gruemayer, Renate; Petersen, Britt S.; Raeder, Benjamin; Ralser, Meryem; Rosenstiel, Philip; Schaefer, Daniel; Schrappe, Martin; Schreiber, Stefan; Schuette, Moritz; Stade, Bjoern; Thiele, Ralf; von der Weid, Nicolas; Vora, Ajay; Zaliova, Marketa; Zhang, Langhui; Zichner, Thomas; Zimmermann, Martin; Lehrach, Hans; Borkhardt, Arndt; Bourquin, Jean-Pierre; Franke, Andre; Korbel, Jan O.; Stanulla, Martin; Yaspo, Marie-LaureTCF3-HLF-positive acute lymphoblastic leukemia (ALL) is currently incurable. Using an integrated approach, we uncovered distinct mutation, gene expression and drug response profiles in TCF3-HLF-positive and treatment-responsive TCF3-PBX1-positive ALL. We identified recurrent intragenic deletions of PAX5 or VPREB1 in constellation with the fusion of TCF3 and HLF. Moreover somatic mutations in the non-translocated allele of TCF3 and a reduction of PAX5 gene dosage in TCF3-HLF ALL suggest cooperation within a restricted genetic context. The enrichment for stem cell and myeloid features in the TCF3-HLF signature may reflect reprogramming by TCF3-HLF of a lymphoid-committed cell of origin toward a hybrid, drug-resistant hematopoietic state. Drug response profiling of matched patient-derived xenografts revealed a distinct profile for TCF3-HLF ALL with resistance to conventional chemotherapeutics but sensitivity to glucocorticoids, anthracyclines and agents in clinical development. Striking on-target sensitivity was achieved with the BCL2-specific inhibitor venetoclax (ABT-199). This integrated approach thus provides alternative treatment options for this deadly disease.Item Novel agents for the treatment of childhood leukemia: an update(DOVE MEDICAL PRESS LTD, 2017-01-01) Eryilmaz, Ertugrul; Canpolat, CengizAchieving lower morbidity and higher survival rates in the treatment of childhood leukemia has been a paradigm of success in modern oncology. However, serious long-term health complications occur in very large populations of childhood leukemia survivors, in the case of both acute lymphoid leukemia and acute myeloid leukemia (AML). Additionally, 15\% of acute lymphoid leukemia patients have treatment failures, and rates are even higher in childhood AML. In the last few decades, as a result of well-tested experiments that statistically analyzed treatment cohorts, new agents have emerged as alternatives or supplements to established treatments, in which high survival and/or less morbidity were observed. This review provides an overview of better practice in the treatment of childhood leukemia.